Etaracizumab, formerly referred to as MEDI523 and subsequently LM609, represents a novel strategy in antibody-mediated therapy. This humanized protein is designed to precisely inhibit the activity of complement protein , a essential component of the cascade involved in immune response . Studies have explored its possible use in different autoimmun